IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1139
Positioning
Market Dominance
Services
Healthcare
$3.1B
Matthew S. Morris
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices. It offers technology and population health tools to enhance independent providers' workflows.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = PRVA ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$PRVA Privia Health Group, Inc. | 56 | 68 | 45 | 65 | 117.0x | 94.0x | 3.0% | 1.7% | 89.0% | 1.4% | 1.1% | 37.4% | 0.0% | 77.0x | $3.1B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
Privia Health Group, Inc. (PRVA) receives a "Hold" rating with a composite score of 56.1/100. It ranks #1139 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for PRVA.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 68 | 84 | -16DRAG |
| MOMENTUM | 65 | 73 | -8DRAG |
| VALUATION | 45 | 45 | 0NEUTRAL |
| INVESTMENT | 30 | 33 | -3NEUTRAL |
| STABILITY | 87 | 95 | -8DRAG |
| SHORT INT | 48 | 46 | +2NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 3.0% (sector 5.7%)
GM 89% vs sector 65%, OM 1% vs sector 5%
Capital turnover N/A
Rev growth 37%, 5yr history
Interest coverage N/A, Net debt/EBITDA -30.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Privia Health Group, Inc. (PRVA) as a Hold with a composite score of 56.1/100 at a current price of $21.52. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Privia Health Group, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 56.1/100 places it at rank #1139 in our full universe.
The near-term outlook is constructive, with revenue growing at 37% and momentum in the 65th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Narrow
Low
Poor
Fair Value
Gross margins of 89% signal strong pricing power.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 117.0x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
Privia Health Group, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns Privia Health Group, Inc. a Hold rating, with a composite score of 56.1/100 and 3 out of 5 stars. Ranked #1139 of 7,333 stocks, PRVA presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
PRVA earns a quality score of 68/100, indicating above-average business quality. The company reports a return on equity of 3.0% (sector avg: 5.7%), gross margins of 89.0% (sector avg: 64.6%), net margins of 1.1% (sector avg: 2.8%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
With a value score of 45/100, PRVA appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 116.99x, an EV/EBITDA of 94.01x, a P/B ratio of 3.55x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Privia Health Group, Inc.'s investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 37.4% vs. a sector average of 8.6% and a return on assets of 1.7% (sector: 2.4%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PRVA demonstrates moderate momentum with a score of 65/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 37.4% year-over-year, while a beta of 0.55 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
Privia Health Group, Inc. earns an excellent stability score of 87/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.55 and a debt-to-equity ratio of 77.00x (sector avg: 0.3x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
The short interest score of 48/100 for PRVA suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 77.00x). With a $3.1B market cap (mid-cap), Privia Health Group, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Privia Health Group, Inc. is a mid-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #1139 of 7,333 overall (84th percentile). Key comparisons include ROE of 3.0% trailing the 5.7% sector median and operating margins of 1.4% below the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While PRVA currently exhibits a HOLD profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Key factor gap
Stability (87) vs Investment (30) — closing this gap could shift the rating.
EV/EBITDA 701% ABOVE SECTOR MEDIAN
ROE 47% BELOW SECTOR MEDIAN
Gross Margin 38% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
As February begins, the U.S. stock market has shown significant strength, with major indexes like the Dow Jones Industrial Average and S&P 500 posting notable gains. This positive momentum in the market presents a timely opportunity to explore stocks that might be trading below their estimated fair value. Identifying undervalued stocks requires careful analysis of both market conditions and individual company fundamentals, offering potential for investors seeking value in a robust financial...
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology for providers industry, including Astrana Health (NASDAQ:ASTH) and its peers.
Ratings for Privia Health Gr (NASDAQ:PRVA) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 3 2 0 0 Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $26.42, a high estimate of $37.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.92%. Decoding Analyst Ratings: A Detailed Look The standing of Privia Health Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jailendra Singh Truist Securities Lowers Buy $24.00 $28.00 Richard Close Canaccord Genuity Lowers Buy $26.00 $37.00 Craig Jones Stifel Lowers Buy $24.00 $28.00 Daniel Grosslight Citigroup Announces Buy $25.00 - Richard Close Canaccord Genuity Lowers Buy $37.00 $41.00 Lisa Gill JP Morgan Lowers Overweight $30.00 $38.00 Andrew Mok Barclays Announces Equal-Weight $22.00 - Andrew Mok UBS Lowers Buy $29.00 $31.00 Gary Taylor TD Cowen Lowers Outperform $26.00 $30.00 Jailendra Singh Truist Securities Lowers Buy $28.00 $32.00 Elizabeth Anderson Evercore ISI Group Lowers Outperform $25.00 $26.00 Adam Ron B of A Securities Lowers Neutral $21.00 $27.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions ...Full story available on Benzinga.com
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?